Approval · Notice of Compliance 4775 · 2004
AVANDAMET: Notice of Compliance 4775
Issued June 22, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 4775
- Date
- June 22, 2004
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the product monograph
- Therapeutic class
- Antidiabetic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AVANDAMET | Not yet assigned | — |
Medicinal ingredients
- METFORMIN HYDROCHLORIDE 500 MG per TAB
- ROSIGLITAZONE MALEATE 1 MG per TAB
- ROSIGLITAZONE MALEATE 2 MG per TAB
- ROSIGLITAZONE MALEATE 4 MG per TAB
- METFORMIN HYDROCHLORIDE 1,000 MG per TAB